EA035578B1 - Терапевтическое лечение раковой кахексии на основе анаморелина - Google Patents

Терапевтическое лечение раковой кахексии на основе анаморелина Download PDF

Info

Publication number
EA035578B1
EA035578B1 EA201790352A EA201790352A EA035578B1 EA 035578 B1 EA035578 B1 EA 035578B1 EA 201790352 A EA201790352 A EA 201790352A EA 201790352 A EA201790352 A EA 201790352A EA 035578 B1 EA035578 B1 EA 035578B1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
anamorelin
cachexia
patients
body mass
Prior art date
Application number
EA201790352A
Other languages
English (en)
Russian (ru)
Other versions
EA201790352A1 (ru
Inventor
Уилльям Манн
Джон Френд
Уилльям Полвино
Сьюзан Аллен
Мин Лу
Элизабет Дуус
Рубен Джорджино
Энрико Барони
Original Assignee
Хелсинн Хелскеа Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA035578(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Хелсинн Хелскеа Са filed Critical Хелсинн Хелскеа Са
Publication of EA201790352A1 publication Critical patent/EA201790352A1/ru
Publication of EA035578B1 publication Critical patent/EA035578B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EA201790352A 2014-09-04 2015-08-28 Терапевтическое лечение раковой кахексии на основе анаморелина EA035578B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (2)

Publication Number Publication Date
EA201790352A1 EA201790352A1 (ru) 2017-07-31
EA035578B1 true EA035578B1 (ru) 2020-07-09

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790352A EA035578B1 (ru) 2014-09-04 2015-08-28 Терапевтическое лечение раковой кахексии на основе анаморелина

Country Status (44)

Country Link
US (5) US9675600B2 (pt)
EP (2) EP3590338A3 (pt)
JP (3) JP6356907B2 (pt)
KR (3) KR102234319B1 (pt)
CN (5) CN107205389A (pt)
AP (1) AP2017009772A0 (pt)
AR (1) AR103118A1 (pt)
AU (1) AU2015312231B2 (pt)
BR (1) BR112017003552A2 (pt)
CA (1) CA2959158A1 (pt)
CL (1) CL2017000494A1 (pt)
CO (1) CO2017003263A2 (pt)
CR (1) CR20170121A (pt)
CY (1) CY1122746T1 (pt)
DK (1) DK3188599T3 (pt)
DO (1) DOP2017000055A (pt)
EA (1) EA035578B1 (pt)
EC (1) ECSP17019893A (pt)
ES (1) ES2761777T3 (pt)
GE (1) GEP20186939B (pt)
HR (1) HRP20192345T1 (pt)
HU (1) HUE046894T2 (pt)
IL (1) IL250692B (pt)
JO (1) JO3541B1 (pt)
LT (1) LT3188599T (pt)
MA (1) MA40607B1 (pt)
MD (1) MD4710C1 (pt)
ME (1) ME03597B (pt)
MX (1) MX361741B (pt)
MY (1) MY187167A (pt)
NI (1) NI201700024A (pt)
PE (1) PE20171109A1 (pt)
PH (1) PH12017500392A1 (pt)
PL (1) PL3188599T3 (pt)
PT (1) PT3188599T (pt)
RS (1) RS59751B1 (pt)
SG (1) SG11201701567UA (pt)
SI (1) SI3188599T1 (pt)
SV (1) SV2017005400A (pt)
TN (1) TN2017000040A1 (pt)
TW (1) TWI639429B (pt)
UA (1) UA120765C2 (pt)
UY (1) UY36286A (pt)
WO (1) WO2016036598A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
AP2017009772A0 (en) 2014-09-04 2017-02-28 Helsinn Healthcare Sa Medical treatments based on anamorelin
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
CA3158632A1 (en) 2019-10-24 2021-04-29 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
TW202327596A (zh) * 2021-09-17 2023-07-16 瑞士商赫爾辛保健公司 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
US20070004638A1 (en) * 2004-06-29 2007-01-04 Rejuvenon Corporation Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
US20080207640A1 (en) * 2007-02-13 2008-08-28 Sapphire Therapeutics Method of treating cell proliferative disorders using growth hormone secretagogues
US20080300194A1 (en) * 2007-04-10 2008-12-04 Sapphire Therapeutics, Inc. Methods of treating emesis using growth hormone secretagogues
WO2013158874A1 (en) * 2012-04-20 2013-10-24 Helsinn Healthcare Sa Methods of producing anamorelin hydrochloride having controlled chloride content
WO2013175805A1 (en) * 2012-05-25 2013-11-28 Raqualia Pharma Inc. Ghrelin receptor agonists for the treatment of achlorhydria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
JP2007531769A (ja) 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
AP2017009772A0 (en) 2014-09-04 2017-02-28 Helsinn Healthcare Sa Medical treatments based on anamorelin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
US20070004638A1 (en) * 2004-06-29 2007-01-04 Rejuvenon Corporation Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
US20080207640A1 (en) * 2007-02-13 2008-08-28 Sapphire Therapeutics Method of treating cell proliferative disorders using growth hormone secretagogues
US20080300194A1 (en) * 2007-04-10 2008-12-04 Sapphire Therapeutics, Inc. Methods of treating emesis using growth hormone secretagogues
WO2013158874A1 (en) * 2012-04-20 2013-10-24 Helsinn Healthcare Sa Methods of producing anamorelin hydrochloride having controlled chloride content
WO2013175805A1 (en) * 2012-05-25 2013-11-28 Raqualia Pharma Inc. Ghrelin receptor agonists for the treatment of achlorhydria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Abernethy A.P. et al., "Anamorelin for the treatment of cancer anorexia-cachexia: Baseline characteristics from three phase III clinical trials (the ROMANA program)", 50th Annual Meeting of the American-Society-of-Clinical-Oncology Location: Chicago, IL, Journal of Clinical Oncology; 20 May 2014, vol. 32(15), supplement S, meeting abstract e20694; 1 p.; entire document *

Also Published As

Publication number Publication date
CN107205389A (zh) 2017-09-26
DOP2017000055A (es) 2017-08-15
ECSP17019893A (es) 2017-05-31
US20240024303A1 (en) 2024-01-25
JP2018154655A (ja) 2018-10-04
IL250692A0 (en) 2017-04-30
SG11201701567UA (en) 2017-03-30
MD20170025A2 (ro) 2017-07-31
CN109172575A (zh) 2019-01-11
MA40607B1 (fr) 2019-11-29
MX361741B (es) 2018-12-14
CN107375285A (zh) 2017-11-24
UA120765C2 (uk) 2020-02-10
KR102307275B1 (ko) 2021-09-30
MX2017002825A (es) 2017-09-28
EP3188599A1 (en) 2017-07-12
RS59751B1 (sr) 2020-02-28
US11723902B2 (en) 2023-08-15
SI3188599T1 (sl) 2020-02-28
UY36286A (es) 2016-02-29
LT3188599T (lt) 2019-12-10
JP2021080281A (ja) 2021-05-27
CO2017003263A2 (es) 2017-07-28
TN2017000040A1 (en) 2018-07-04
CR20170121A (es) 2017-07-17
EP3188599A4 (en) 2017-10-11
PT3188599T (pt) 2020-01-15
US20190175574A1 (en) 2019-06-13
TW201613587A (en) 2016-04-16
KR20180085047A (ko) 2018-07-25
ES2761777T3 (es) 2020-05-21
AP2017009772A0 (en) 2017-02-28
CA2959158A1 (en) 2016-03-10
EP3188599B1 (en) 2019-10-02
WO2016036598A1 (en) 2016-03-10
JO3541B1 (ar) 2020-07-05
US10894041B2 (en) 2021-01-19
US20160067236A1 (en) 2016-03-10
EP3590338A3 (en) 2020-03-18
AU2015312231A1 (en) 2017-03-23
ME03597B (me) 2020-07-20
GEP20186939B (en) 2018-12-25
JP7044918B2 (ja) 2022-03-30
US20210093627A1 (en) 2021-04-01
JP2017526695A (ja) 2017-09-14
JP6356907B2 (ja) 2018-07-11
PE20171109A1 (es) 2017-08-07
NZ729673A (en) 2023-09-29
BR112017003552A2 (pt) 2017-12-05
PL3188599T3 (pl) 2020-06-01
MD4710C1 (ro) 2021-04-30
HUE046894T2 (hu) 2020-04-28
AU2015312231B2 (en) 2017-10-19
EP3590338A2 (en) 2020-01-08
AR103118A1 (es) 2017-04-19
US9675600B2 (en) 2017-06-13
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
KR102234319B1 (ko) 2021-04-01
TWI639429B (zh) 2018-11-01
SV2017005400A (es) 2017-04-20
JP6923486B2 (ja) 2021-08-18
KR20210035923A (ko) 2021-04-01
CN113577074A (zh) 2021-11-02
CN113577073A (zh) 2021-11-02
MY187167A (en) 2021-09-07
NI201700024A (es) 2017-07-18
HRP20192345T1 (hr) 2020-03-20
KR101881264B1 (ko) 2018-07-23
KR20170047372A (ko) 2017-05-04
IL250692B (en) 2019-05-30
CL2017000494A1 (es) 2017-09-15
US20170296526A1 (en) 2017-10-19
US10278964B2 (en) 2019-05-07
CY1122746T1 (el) 2021-03-12
MD4710B1 (ro) 2020-09-30
PH12017500392B1 (en) 2017-07-17
PH12017500392A1 (en) 2017-07-17

Similar Documents

Publication Publication Date Title
US11723902B2 (en) Medical treatments based on anamorelin
Muñoz et al. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists
JP2022009657A (ja) リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
WO2019008571A1 (en) SYSTEM AND METHOD SPECIFIC TO A SUBJECT FOR PREVENTING BODY ADAPTATION TO CHRONIC DISEASE TREATMENT
WO2019100003A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
OA18229A (en) Medical treatments based on anamorelin.
US20210060130A1 (en) Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug
TW202327596A (zh) 於厭食/惡病體質患者針對患者自述結果判定及提供臨床有意義改善之方法
NZ729673B2 (en) Medical treatments based on anamorelin
Kim et al. Complications of Anticancer Drugs and Their Management
WO2017151360A1 (en) Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastoma